A prominently published study reported an improvement in mortality in acute respiratory distress syndrome (ARDS) patients who received early treatment with the paralyzing agent cisatracurium.

During the first 48 hours after randomization, 488 of the 501 patients (97.4%) in the intervention group started a continuous infusion of cisatracurium (median duration of infusion, 47.8 hours ...

In patients undergoing mechanical ventilation for the acute respiratory distress syndrome (ARDS), neuromuscular blocking agents may improve oxygenation and decrease ventilator-induced lung injury ...

Background. We devised this study to quantify the effect of age on the consumption of cisatracurium under general anaesthesia, using a computer controlled closed loop infusion system. We further ...

(“Meitheal”), announced today that it is voluntarily recalling one (1) lot of Cisatracurium Besylate Injection, USP 10mg per 5mL to the user level. The decision to recall the product was made ...

Hikma is offering cisatracurium besylate injection in 200mg/20ml and 20mg/10ml doses. The product is indicated as an adjunct to general anesthesia to facilitate tracheal intubation in adults and ...

the company announced today through an exchange filing. According to IQVIATM (IMS Health), Cisatracurium Besylate Injection USP had US sales of approximately $35 million for the 12- month period ...

Generic drug maker Meitheal Pharmaceuticals recalled one lot of cisatracurium besylate, a muscle relaxant, after what the Institute for Safe Medication Practices called an "extremely hazardous ...

The company is recalling one lot of Cisatracurium Besylate Injection, USP 10mg per 5mL because of mislabeling. Meitheal Pharmaceuticals announced on Jan. 27, 2021 that is voluntarily recalling one lot ...